Unraveling the Heterogeneity of Tumor Immune Microenvironment in Hepatocellular Carcinoma by Single-Cell RNA Sequencing and its Implications for Prognosis and Therapeutic Response Authors: Ying Han, Lele Song, Lingna Lv, Chunlei Fan, Huiguo Ding Published: 2024 ABSTRACT Tumor immune microenvironment (TIME) has become a new hotspot in cancer research over the past few years. Tumor immune microenvironment of hepatocellular carcinoma (HCC) is especially intriguing as HCC is reported to be highly heterogeneous by previous genomic and cytological studies. It is also closely related to patient prognosis and therapeutic outcome. The recently emerged single-cell RNA sequencing (scRNAseq) technique provides a new tool for TIME study, and current studies have made great advances in defining the roles of TIME in HCC pathogenesis and therapy. Current evidence suggests that heterogeneity is a key player influencing therapeutic response, drug resistance, and prognosis. However, our understanding is limited on the roles of TIME heterogeneity in HCC development, prognosis, and therapeutic response, especially in the era of immunotherapy. This review aims to unravel the heterogeneity of TIME in HCC by scRNAseq, with specific focuses on the cellular, transcriptional, and marker perspectives of TIME heterogeneity in HCC, as well as assessing prognostic and therapeutic response by heterogeneity markers. By summarizing current discoveries regarding TIME heterogeneity, we hope to provide clues on the crucial roles of various cellular components in the development and progression of HCC. We also hope to identify potential markers and therapeutic targets for prognosis assessment and personalized treatment to improve patient outcomes. Combined therapies from multiple dimensions regarding heterogeneity may provide new opportunities to treat HCC more effectively. Main Points scRNAseq provides a powerful new tool to define the roles of TIME in HCC pathogenesis and therapy. scRNAseq provides a powerful new tool to define the roles of TIME in HCC pathogenesis and therapy. HCC heterogeneity is a key player influencing therapeutic response, drug resistance, and prognosis. HCC heterogeneity is a key player influencing therapeutic response, drug resistance, and prognosis. Heterogeneous cellular components, differentially transcripted genes, specific markers, and relevant models have been discovered or established to predict HCC patient prognosis and therapeutic response. Heterogeneous cellular components, differentially transcripted genes, specific markers, and relevant models have been discovered or established to predict HCC patient prognosis and therapeutic response. Combined therapies from multiple dimensions regarding heterogeneity may provide new opportunities to treat HCC more effectively. Combined therapies from multiple dimensions regarding heterogeneity may provide new opportunities to treat HCC more effectively. Introduction Tumor immune microenvironment (TIME) is a local ecosystem composed of tumor cells, immune cells, stromal cells, and various intracellular and intercellular factors. Tumor immune microenvironment heterogeneity remains a major challenge in cancer prevention and treatment.1,2 Genomic, transcriptomic, and epigenomic studies have revealed widespread intra-tumor and inter-tumor heterogeneity. Heterogeneity of TIME is a major contributing factor to tumor metastasis, recurrence, and drug resistance, but the relationship between distinct TIME subtypes and the clinical relevance of hepatocellular carcinoma (HCC) is currently unclear. Chronic hepatitis due to viral infection, stress, drug-induced liver damage, aflatoxin-contaminated food, untreated inflammation, and complex tumor microenvironment led to high intratumoral heterogeneity.3,4 Recent single-cell sequencing studies, particularly those using the single-cell RNA sequencing (scRNAseq) technique, have greatly improved our understanding of the TIME heterogeneity, especially the characteristics of immune cell subsets and tumor-associated stromal cells.5,6 Despite recent advances in HCC immunotherapy, our knowledge of the relationship between HCC TIME and patient outcomes is limited, and more research is still required. This review focuses on findings of HCC TIME heterogeneity and its roles in prognosis and response revealed by the scRNAseq technique. Composition of HCC TIME and its Roles in HCC Pathogenesis The cellular component of HCC TIME consists of non-immune cells (normal liver cells and tumor cells) and immune cells. The non-immune cells mainly include normal epithelial cells, normal endothelial cells, hepatic stellate cells, and HCC malignant cells. Most of the non-immune cells in cancer patients are malignant, while endothelial cells and hepatic stellate cells are relatively low in proportion.7 The immune cells identified include T cells, myeloid cells, plasma cells, B cells, and natural killer (NK) cells. Hepatocellular carcinoma patients had relatively low levels of infiltration of dendritic cells (DCs), B cells, and plasma cells. The proportion of immune cell populations varies in different patients, indicating significant heterogeneity of immune cell composition across HCC malignancies.7 The myeloid cells can be divided into 11 clusters, including 5 macrophage clusters, 2 monocyte clusters, 3 dendritic cell clusters, and 1 circulating cell cluster. The reclustering of T/NK cells showed 17 clusters, including 2 NK subtypes, 4 CD4+ T cell subtypes, and 7 CD8+ T cell subtypes.7 The immune cells in HCC can be divided into 2 types, one immunoactive type promoting anti-tumor immune responses and one immunosuppressive type limiting effective immune monitoring. Immunoactive cells mainly include CD8+ T cells, dendritic (DC) cells, tumor-associated macrophages (TAM) type M1, and NK cells. It was reported that CD8+ T cells attack cancer cells by producing direct cytotoxic effects through perforin and granzyme secretion.8 Dendritic cells capture tumor antigens. Tumor-associated macrophages (type M1) activates the T-cell-mediated immune response, promotes inflammation, and secretes tumor necrosis factor α (TNF-α) and nitric oxide (NO).9 Natural killer cells attack infected and mutated cells by secreting cytokines and chemokines such as TNF-α and interferon-gamma (IFN-γ), interacting with other immune cells.10 Immunosuppressive cell populations in HCC TIME include TAM (type M2), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), causing dysfunction of DCs and CD8+ T cells.11 LAMP3+ DC may belong to a common DC subgroup with mature characteristics and may play a role in T cell dysfunction.12 Different pathogenesis of HCC involving viral and non-viral etiology is related to the unique TIME. Chronic infection with hepatitis B virus (HBV) promotes the formation of a tolerant TIME by depletion of the effector CD8+ T cells and attracting immunosuppressive cells including granulomatous myeloid-derived suppressor cells (gMDSCs), Tregs, or regulatory B (Breg) cells. Chronic infection by hepatitis C virus (HCV) depletes CD8+ T cells and promotes immune evasion through spontaneous viral escape and dysregulation of major histocompatibility complex I (MHC I) dependent antigen presentation.13,14 In alcoholic steatohepatitis (ASH), alcohol promotes the inhibition of liver immune response by increasing the abundance of M2 TAMs, inhibiting CD8+ T cell activation, and facilitating gMDSC infiltration. In contrast, non-alcoholic steatohepatitis (NASH) activates dysfunctional immune cells, including helper T cell 17 (Th17) cells, natural killer T (NKT) cells, CD8+/PD-1+ T cells and IgA+ plasma cells, disrupting tumor immune surveillance and inducing HCC.15,16 HCC can be divided into 2 types in terms of immune response. One is the “inflammatory type,” which includes 3 distinct subtypes: immunologically “active” tumors with high levels of infiltration of CD8+ T cells and TAM (type M1) and interferon signaling, immunologically “depleted” tumors characterized by high levels of transforming growth factor-β (TGF-β) signaling, increased Wnt/β-catenin signaling and abundant TAM (type M2). The third subtype is associated with high levels of chromosomal instability and dysfunction of antigen presentation and interferon signaling, and this subtype also involves those with high levels of Wnt/β-catenin signaling and immune desertification characteristics.17-19 The TIME Heterogeneity in HCC The TIME heterogeneity of HCC reported in current studies can be divided into 2 categories: cellular heterogeneity and transcriptional heterogeneity. Articles that describe the TIME heterogeneity of HCC are summarized in Table 1.13,20-52 Cellular Heterogeneity Cellular heterogeneity is the most studied direction, involving heterogeneity of immune cell type, proportion, and distribution (Table 1). One study defined 25 cell clusters, labeled them by marker genes, and found differences in the abundance of 16 cell subgroups between tumor and normal tissues.20 Subsequent studies discovered immune cell clusters or subsets from diverse perspectives. One early study revealed 11 subclusters with different cytotoxicity, exhaustion, and activation.21 Another study stratified patients into 5 TIME subtypes based on heterogeneous cellular immune status, including 2 immune suppression subtypes mediated by myeloid or stromal cells, one immune activation subtype, one immune exclusion subtype, and one immune residence subtype.22 Similarly, another study grouped HCC into 3 subtypes, including a “hot tumor,” a “cold tumor” and an “immunosuppressed tumor” subtype.23 Furthermore, heterogeneity was also revealed in terms of metabolic status. For example, HCC was classified into 2 distinct clusters by metabolic status: one cluster showed high fatty acid oxidation and glutaminolysis status, and the other cluster showed high levels of glycolysis and pentose phosphate pathway activity.24 Another study classified the epithelial cells of HCC into 2 metabolism-related subpopulations, one pertaining to amino acid metabolism and the other to glycolysis.25 These studies revealed heterogeneity of diverse subsets of immune cells in HCC, not only in cell types but also in cell functions. Many studies have also investigated the heterogeneity of subpopulations for certain types of immune cells in HCC. B cells, T cells and NK cells were among those that were investigated the most. One study defined the abundance and location of T cell subsets and found that infiltration of exhausted CD8+ T cells, CD8+ T cells, and FOXP3+ Tregs was related to patient prognosis.26 Another study discovered that CD8+ T cells in HCC can be divided into 7 subsets. TP53-mutant and nonmutant groups showed considerable differences in one cytotoxic CD8+ T cell subset in a series of clinicopathological factors. Meanwhile, different CD8+ T cell subsets exhibited heterogeneous prognosis in HCC, and one cytotoxic CD8+ T cell subset was closely associated with HCC prognosis.27 Regarding B cells, one study identified several subtypes of B cells and revealed that the relative ratio of B cells was significantly decreased in HCC. It further suggested that antigen presentation and cell proliferation were downregulated in tumor-infiltrating B cells, and a higher rate of B-cell infiltration was related to better prognosis.28 Another study identified 6 clusters of B cells and classified them into plasma cells and activated or exhausted B cells. Higher metabolic activity was found in the activated B and plasma cells than in exhausted B cells.29 Furthermore, high proliferation, low differentiation, and low activity were found in memory B cells in HCC.30 The NK cells have been less investigated in terms of subpopulations compared with T and B cells. One study discovered 2 NK cell subsets with different cytotoxic capacities, including one subset with an exhausted status and the other subset in an activated state.30 The activated NK cells exerted an anti-tumor effect, while the exhausted NK cells exhibited a pro-tumor effect. The observations in T, B, and NK cell subpopulations suggested huge heterogeneity of immune cell function in HCC and its influence on the interaction between TIME and immune cells. The heterogeneity of cancer-associated fibroblasts (CAFs) was also suggested to contribute to HCC development and was investigated by some studies. The proportion of CAFs appeared to stratify patient prognosis and response to therapy. It was reported that the CAF high cluster was associated with a higher level of inflammatory cell infiltration, a more immunosuppressive microenvironment, and a worse prognosis. The CAF high cluster could have a better response to PD-1 blockade, while the CAF low cluster may be more sensitive to transarterial chemoembolization treatment.31 Cancer-associated fibroblasts were also shown to influence the metabolism in HCC. The CAF high cluster exhibited lower levels of aerobic oxidation and higher angiogenic scores.31 High-level lipid metabolism and mediated oxidized low-density lipoprotein (LDL) uptake-dependent migration inhibitory factor (MIF) expression were found in CD36+ CAFs. It is possible that CD36 inhibitors synergized with anti-PD-1 immunotherapy by restoring antitumor T-cell responses.31 It can be seen from the above studies and those summarized in Table 1 that some reports identified heterogeneous cell clusters while others revealed specific immune cell subtypes. Although these studies focused on cellular heterogeneity in HCC from different perspectives, they all highlighted the diversity of immune cells and their transcriptional status and their potential roles in HCC development, invasion, metastasis and patient therapeutic response and prognosis. Although intratumor and intertumor heterogeneity was present in HCC patients at different stages or with different etiology, the cellular heterogeneity appeared to be prominent in HCC at identical stages and etiology. Identification of reliable cellular markers on heterogeneity that can be used to guide clinical practice may be a promising research direction. Transcriptional Heterogeneity Apart from cellular heterogeneity, some studies focused on transcriptional heterogeneity (Table 1). Transcriptional heterogeneity was shown to be extensively present in HCC by scRNA-seq. An early study identified 29 immune cell subsets with specific transcriptional profiles in HCC,13 in which 4 subsets of macrophages, 6 distinct NK clusters, diverse CD8+ T-cell subsets, and increased cell–cell interactions were identified. A subset of M2 macrophages with high cAMP responsive element modulator (CREM) expression and C-C Motif Chemokine 18 (CCL18) expression was revealed in advanced HCC, suggesting its potential roles in tumor progression.13 Another study found a varying degree of transcriptomic diversity in HCC. Specifically, T cells showed lower cytolytic activity in more heterogeneous tumors, and tumor-derived vascular endothelial growth factor (VEGF) drove microenvironmental reprogramming, suggesting a diverse ecosystem of HCC.32 A later study classified HCC into 2 clusters by differentially expressed genes (DEGs) in energy metabolism and showed that malignant cells of HCC had the highest overall metabolic activities. Metabolic competition may impair the anti-tumor capacity of CD8+ T cells.24 Similarly, another study also classified the epithelial cells from HCC patients into 2 metabolism-related subpopulations and found that the subtype promoting glycolysis exhibited high fructose-bisphosphate aldolase A (ALDOA) expression and was associated with an immunosuppressive TIME.25 Furthermore, a recent study revealed that the transcription of genes related to glucose and lipid metabolism changed in an HCC subpopulation, suggesting their potential roles as prognostic biomarkers.33 The above observations on transcriptional heterogeneity suggest that the microenvironment and cellular metabolism within HCC are comprehensively altered due to aberrant transcription. Understanding transcriptional heterogeneity may help to assess patient prognosis and develop new therapeutic strategies. Many specific markers have been discovered in various types of immune cells. Marker-based classification or stratification models have been developed during the investigation of HCC heterogeneity (Table 1). These markers themselves also exhibited heterogeneity. Specific markers related to T cells were investigated. One study observed different distributions of tumor-infiltrating lymphocytes (TILs). CD4-GZMA (Granzyme A) TIL cells showed an association with prognosis and may yield therapeutic benefits in HCC immunotherapy.34 Another study discovered a subset of activated CD8+ T cells that highly expressed XCL1 and correlated with a better survival rate. Effector CD8+ T cells in both early-stage and advanced HCC were found to have distinct transcriptomic signatures, cytotoxic phenotypes, and evolution trajectories.13 A recent study identified SOX4 and DTHD1 as the top DEGs in HCC, which were associated with key interactions between T cells and NK cells.35 Treg cells were found to uniquely overexpress immune checkpoint molecules, including CTLA4, TNFRSF4, and TIGIT. They were also found to enrich the glycolysis/gluconeogenesis pathway.30 In addition, CCL5 overexpression in circulating tumor cells (CTCs) was transcriptionally regulated by p38-MAX signaling, recruiting Tregs to facilitate CTC metastatic seeding and immune escape.36 Markers of NK cells were also investigated. One study categorized HCC patients into 2 subtypes with distinct clinical outcomes based on NK cell marker genes (NKGs). NKscore, a prognostic signature, was established and used to stratify patient risk. The high-risk group represented an immune-exhausted phenotype, and the low-risk group corresponded to strong anti-cancer immunity.37 Another study identified 161 NK cell marker genes related to HCC, 28 of which were significantly associated with patient prognosis, and a prognosis model was established by 10 genes.38 Macrophages also showed specific markers related to heterogeneity. A study identified an M2 macrophage subset with high CCL18 and CREM expression in advanced HCC, which potentially facilitates tumor progression.13 VCAN+ TAMs were found to undergo M2-like polarization and differentiate in tumors. Intensive intercellular crosstalk among regulatory T (Treg) cells, regulatory DCs, exhausted CD8+ T cells, and C1QC+ TAMs may foster immunosuppression in HCC.39 TAM was also suggested to suppress tumor T cell infiltration.40 Furthermore, tumor-associated neutrophil (TAN) populations were found to be enriched and were associated with poor prognosis.22 Markers of malignant hepatocytes were also identified and were correlated with patient prognosis. One recent report revealed malignant hepatocyte clusters with different marker genes and biological functions. TPI1, a key gene in C6_Hepatocyte-IL13RA2 and HCC metastasis, could participate in regulating the HCC immune microenvironment, and its expression was positively correlated with HCC metastasis and poor prognosis, while negatively correlated with CD8+ T cell infiltration.50 In another study, a glycolysis‑related prognostic model divided patients with HCC into high‑ and low‑risk groups, and in vitro analyses revealed that ZFP41 played a crucial role in cell viability, proliferation, migration, invasion, and glycolysis.51 It was clear from the above studies that transcriptional heterogeneity was comprehensive across different cell types and subtypes of the same cell. The heterogeneity of many specific cellular markers has been identified, and the markers were correlated with patient therapeutic response or prognosis. However, different HCC stages and different etiologies may influence the therapeutic response or prognosis. The establishment of models for predicting response or prognosis should consider these influencing factors. Meanwhile, the transcriptional levels of cellular markers could also be affected by these factors. Therefore, future studies should involve these clinicopathological factors when models for response or prognosis assessment are established. Assessment of Prognosis and Therapeutic Response by TIME Heterogeneity of HCC The relationship between the heterogeneity of TIME in HCC and patient prognosis or therapeutic response has been investigated by many studies (Table 1). Individual markers have been found and models have been established to assess patient prognosis and response. Models composed of multiple genes have mostly been used in assessing patient prognosis and response. One study found 19 CD4-GZMA (Granzyme A) cell-specific DEGs as prognostic genes and constructed an immune risk score model with 13 genes by LASSO Cox regression for prognostic assessment. The survival analysis showed a strong association between the risk score and overall survival.34 In another similar study, 36 hub DEG genes were identified between HCC and normal samples, and 10 of them were closely related to HCC patient survival.41 In contrast, a more recent study constructed a model with fewer genes. A 3-gene signature (CSTB, TALDO1, CLTA) was developed based on the heterogeneity of the TIME, and the model showed excellent predictive performance for immunotherapy response and prognosis, in which low-score patients had a better prognosis than high-score patients.20 Some studies identified cell-specific DEGs and used them to construct models for prognosis assessment. One study identified 4 cell subgroups with 641 specific markers and developed a 9-gene prognostic risk model. The model demonstrated good performance in 5-year survival prediction.42 A recent study identified 6 cell subpopulations and revealed 11 prognosis-related DEGs associated with HCC prognosis.33 Another study analyzed cytotoxic CD8+ T cell subsets and found that one of the subsets was closely related to the prognosis and survival of HCC. Ten hub genes were found, and 4 differential genes were identified as potential markers for prognosis, survival, and clinical features of HCC.27 Specific NK cell markers were also identified and used to construct prognostic models. A study discovered 80 prognosis-related NK cell marker genes and established a 5-gene prognostic NKscore. The NKscore can stratify the anti-cancer immunity and the sensitivity in immunotherapy.37 Another study performed integrated analysis of bulk RNA-sequencing and scRNAseq and revealed a signature based on NK cell genes for HCC prognosis prediction. Ten prognostic genes were screened from 28 genes associated with overall survival, and a prognostic model was developed. Higher risk scores correlated with poorer survival and advanced tumor stages.38 A more recent study developed an immune-related signature and stratified HCC into 2 risk subgroups (C1 and C2). C1 had poorer outcomes, a higher CNV burden and malignant scores, higher sensitivity to sorafenib, and an immunosuppressive phenotype. C2 had better outcomes, higher metabolism, and more benefit from immunotherapy. The immuno-prognostic subtypes were conducive to individualized prognosis prediction and treatment options for HCC.49 Specific types of immune cells were also suggested as prognostic markers for patient survival. It was reported that the infiltration of CD8+ T cells was closely linked to recurrence-free survival or the overall.26 Tumor-associated neutrophil populations were also suggested to be associated with poor prognosis.22 Similarly, a neutrophil-derived signature was constructed in one study and showed predictive value for the response to immunotherapy and chemotherapy as well as for HCC patient prognosis.43 Patients with higher B-cell infiltration rates were found to have significantly longer disease-free survival, suggesting a correlation between B-cell infiltration rate with prognosis.28 Apart from immune cells, epithelial cells and CAFs were also suggested to correlate with patient prognosis. A study classified the epithelial cells from HCC patients into 2 metabolism-related subpopulations and found that the glycolysis-related group had significantly worse clinical outcomes due to an immunosuppressive TIME.25 Another study reported that patients in the CAF high cluster had a significantly worse prognosis due to a higher level of inflammatory cell infiltration and a more significant immunosuppressive microenvironment. However, the CAF high cluster could have a better response to PD-1 blockade due to lower levels of aerobic oxidation and higher angiogenic scores. In contrast, the CAF low cluster may be more sensitive to transarterial chemoembolization treatment.31 Studies reviewed above identified a series of markers for the assessment or prediction of therapeutic response and prognosis, including specific cell types, expression of specific marker genes, and signatures. Some of them were validated by data from the database, while others were validated by clinical samples or in vitro experiments. However, there has been no consensus on markers that can be used in HCC patients to guide their clinical diagnosis or treatment. Due to the heterogeneity among studies and patient populations, it is difficult to normalize the conditions in these observations. Meanwhile, transcriptional status itself is highly variable among patients, and different studies may focus on different perspectives. Therefore, the establishment of a standardized dataset/database with methodological uniformity may be required to achieve the goal of finding clinically applicable markers at the transcriptomic level for response and prognosis assessment.53,54 Different Pipelines Used to Analyze the scRNAseq Data In this study, the analysis of scRNAseq data involves several software or processes, among which CellRanger and Seurat are more commonly used than others (Table 1). CellRanger is officially recommended by 10X Genomics for single-cell transcriptome analysis.55,56 CellRanger is a set of analysis pipelines for processing single-cell data, comparing raw fastq data, generating quantitative matrices of expression, performing clustering and other auxiliary analyses, etc. The results are mostly contained in the original web report, with less analysis and less scope to modify and customize the analysis. In contrast, Seurat is an integrated software package for single-cell data analysis developed by the New York Genome Center, Satija Lab.57 Its functions include not only basic data analysis processes, such as quality control, cell screening, cell type identification, feature gene selection, differential expression analysis, data visualization, etc., but also some advanced functions, such as time series single-cell data analysis, single-cell data integration analysis of different omics, etc. After obtaining the result of the cell gene expression matrix based on CellRanger analysis, Seurat software can be used for further analysis. In addition to the above 2 software, there are other self-developed software. The analysis by each software is independent, although there are specific common analysis contents, such as cell clustering, differential gene identification, functional annotation, etc., and the algorithms of different software are not exactly the same. These programs cover the vast majority of what is involved in single-cell analysis, and the script is relatively flexible, allowing parameters and methods to be modified according to specific requirements to obtain the best results. In addition, the results can be adjusted according to the individual needs of certain projects, including the presentation of the results. The specific software used for analysis mainly depends on the user’s choice according to their requirements, as well as the expectations and requirements of the analysis results. For the immune microenvironment analysis in this study, currently published databases, including TIMER, CIBERSORT, immuneCellAI, ABIS, EPIC, etc., provide corresponding online programs that can analyze the immune infiltration of various immune cells in the samples through machine learning and deconvolution algorithms. Future Research Directions It can be seen from this review that extensive studies have been performed to investigate the heterogeneity of HCC in terms of cellular diversity and gene transcription by scRNAseq. However, our understanding of the relationship between heterogeneity and prognosis or therapeutic response is not sufficient and still needs further in-depth investigation. Due to the variation among different cohorts in scRNAseq studies and inter-tumor heterogeneity, a larger sample size may be needed to validate potential biomarkers for prognosis and response. It is also important to define patient characteristics and therapeutic strategies, as these factors may influence the cellular components and transcription. Meanwhile, sequencing and analyzing methods should be standardized to ensure reliable data interpretation. Exploring the potential of combination therapies that simultaneously target multiple populations of immune cells may provide new opportunities to treat HCC more effectively. Moreover, future studies should also explore the interactions and regulatory mechanisms between different immune cell populations in HCC TIME to further understand their roles in tumor development and progression.